Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, Brazil.
BMJ Open. 2019 May 22;9(5):e027489. doi: 10.1136/bmjopen-2018-027489.
Vulvovaginal candidiasis (VVC) is frequent in women worldwide and usually responds rapidly to topical or oral antifungal therapy. However, some women develop recurrent vulvovaginal candidiasis (RVVC), which is arbitrarily defined as four or more episodes every year. RVVC is a debilitating, long-term condition that can severely affect the quality of life of women. Most VVC is diagnosed and treated empirically and women frequently self-treat with over-the-counter medications that could contribute to an increase in the antifungal resistance. The effective treatment of RVVC has been a challenge in daily clinical practice. This review aims to assess the efficacy of antifungal agents administered orally or intravaginally for the treatment of RVVC, in order to define clinical practices that will impact on the reduction of the morbidity and antifungal resistance.
A comprehensive search of the following databases will be carried out: PubMed, Embase, Scopus, Web of Science, Scientific Electronic Library Online (SciELO), the Cochrane Central Register of Controlled Trials (CENTRAL), Biblioteca Virtual em Saúde (Virtual Health Library)/Biblioteca Regional de Medicina (Regional Library of Medicine) (BVS/BIREME), Cumulative Index to Nursing and Allied Health Literature (CINAHL) and in the clinical trials databases (www.trialscentral.org; www.controlled-trials.com; www.clinicaltrials.gov). The risk of bias will be assessed according to the Cochrane Risk of Bias tool. We will perform data synthesis using the Review Manager (RevMan) software V.5.2.3. To assess heterogeneity, we will compute the I2 statistic.
This study will be a review of published data and it is not necessary to obtain ethical approval. Findings of this systematic review will be published in a peer-reviewed journal.
CRD42018093817.
外阴阴道念珠菌病（VVC）在世界各地的女性中很常见，通常对局部或口服抗真菌治疗反应迅速。然而，一些女性会出现复发性外阴阴道念珠菌病（RVVC），RVVC 被任意定义为每年发作 4 次或以上。RVVC 是一种使人虚弱的长期疾病，会严重影响女性的生活质量。大多数 VVC 是经验性诊断和治疗的，女性经常自行使用非处方药物治疗，这可能导致抗真菌耐药性增加。RVVC 的有效治疗一直是日常临床实践中的一个挑战。本综述旨在评估口服或阴道内给予抗真菌药物治疗 RVVC 的疗效，以便确定将影响降低发病率和抗真菌耐药性的临床实践。
将全面检索以下数据库：PubMed、Embase、Scopus、Web of Science、Scientific Electronic Library Online (SciELO)、Cochrane 中央对照试验注册库（CENTRAL）、Biblioteca Virtual em Saúde（虚拟健康图书馆）/Biblioteca Regional de Medicina（区域医学图书馆）（BVS/BIREME）、护理与联合健康文献累积索引（CINAHL）和临床试验数据库（www.trialscentral.org；www.controlled-trials.com；www.clinicaltrials.gov）。将根据 Cochrane 偏倚风险工具评估偏倚风险。我们将使用 Review Manager（RevMan）软件 V.5.2.3 进行数据综合。为了评估异质性，我们将计算 I2 统计量。
本研究将是对已发表数据的综述，不需要获得伦理批准。本系统评价的结果将发表在同行评议的期刊上。
CRD42018093817。
